Review of NICE Technology Appraisal Guidance No. 187;  Infliximab and adalimumab for the treatment of Crohn’s disease 

Proposal to update the existing guidance into a current ongoing clinical guideline

The planned date for review of the above Technology Appraisal guidance was September 2011.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full appraisal review.

Having re-looked at the guidance and the possible scope for a review, we believe that this topic would be better dealt with within the context of a clinical guideline. Consequently we propose that the review of the original guidance be incorporated into the on-going NICE guideline on Crohn’s disease: ‘The management of Crohn’s disease’, which is currently due for release to the NHS at the end of 2012.

TA187 will remain in existence alongside the clinical guideline and will be moved to the static guidance list.  This proposal will have the consequence of preserving the funding direction that is linked to the technology appraisal.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.  Please see appendix A for a full list of the organisations we have contacted.

January 2011

• Appendix A: Matrix of stakeholders
• Appendix B: Proposal paper presented to the Institute's Guidance Executive